This is a preprint.
Relationships between blood pressure indicators and fluid biomarkers of brain aging in functionally intact older adults
- PMID: 40196000
- PMCID: PMC11975004
- DOI: 10.21203/rs.3.rs-6018137/v1
Relationships between blood pressure indicators and fluid biomarkers of brain aging in functionally intact older adults
Update in
-
Relationships between blood pressure indicators and fluid biomarkers of brain aging in functionally intact older adults.Alzheimers Res Ther. 2025 Apr 21;17(1):85. doi: 10.1186/s13195-025-01731-9. Alzheimers Res Ther. 2025. PMID: 40259431 Free PMC article.
Abstract
Background: Dementia risk is significantly shaped by cardiovascular health, with elevated blood pressure emerging as a key risk factor for adverse brain aging. Blood biomarkers such as pTau181, Aβ42/40, NfL, and GFAP have improved our understanding of dementia pathophysiology, however, few studies have explored how specific blood pressure metrics relate to biomarker levels, which could inform personalized dementia prevention strategies as these biomarkers move into clinic. We examined how different blood pressure metrics associated with molecular markers of astrocytic activation (GFAP), neuronal axon breakdown (NfL), and Alzheimer's disease pathobiology (pTau181, Aβ42/40) in plasma.
Methods: 109 functionally intact (Clinical Dementia Rating Scale=0) older adults completed blood draws with plasma assayed for Aβ42/40, GFAP, NfL, and pTau181 (Quanterix Simoa) and in-lab blood pressure quantification. Blood pressure metrics included diastolic blood pressure, systolic blood pressure, and pulse pressure (systolic minus diastolic). Separate regression models evaluated plasma biomarkers as a function of each blood pressure metric, adjusting for age and biological sex. Interaction models tested whether relationships between blood pressure metrics and plasma biomarkers differed by sex, age, or APOE-ε4 status.
Results: With the exception of Aβ42/40, higher pulse pressure related to higher levels of all plasma biomarkers examined (pTau181, NfL, GFAP). Additionally, higher systolic blood pressure related to higher pTau181, while diastolic blood pressure did not meaningfully associate with any biomarker. Interaction models revealed a significantly stronger relationship between elevated pulse pressure and higher GFAP concentrations in females compared to males, as well as a significantly stronger association between elevated pulse pressure and lower Aβ42/40 plasma concentrations in APOE-ε4 carriers compared to non-carriers.
Conclusions: Our findings suggest that elevated pulse pressure, and to a lesser extent systolic blood pressure, are associated with increased Alzheimer's disease and neurodegenerative (axonal and astrocytic health) biology among typically aging adults. These associations underscore the importance of blood pressure management, particularly pulse pressure, for reducing dementia risk. Cardiovascular health may be incorporated with biomarkers to further personalize dementia prevention and management strategies.
Keywords: astrocytic activation; axonal breakdown; blood pressure; cardiovascular health; pulse pressure.
Conflict of interest statement
Competing interests JHK receives royalties from Pearson’s Inc. JCR is a site principal investigator for clinical trials sponsored by Eli-Lilly, Eisai and Amylyx. The authors report no other conflict of interest. Additional Declarations: Competing interest reported. JHK receives royalties from Pearson’s Inc. JCR is a site principal investigator for clinical trials sponsored by Eli-Lilly, Eisai and Amylyx. The authors report no other conflict of interest.
Figures
References
-
- The Lancet Public Health. Reinvigorating the public health response to dementia. Lancet Public Health [Internet]. 2021. [cited 2024 Apr 30];6:e696. Available from: http://www.thelancet.com/article/S2468266721002152/fulltext - PMC - PubMed
-
- Livingston G, Huntley J, Sommerlad A, Ames D, Ballard C, Banerjee S et al. The Lancet Commissions Dementia prevention, intervention, and care: 2020 report of the Lancet Commission The Lancet Commissions. thelancet.com [Internet]. 2020. [cited 2023 May 23];396:413–59. Available from: 10.1016/S0140-6736(20)30367-6 - DOI - PMC - PubMed
-
- Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer’s disease: an analysis of population-based data. Lancet Neurol. 2014;13:788–94. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous
